| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 07/07/2004 | EP1434772A1 Compounds and methods |
| 07/07/2004 | EP1434763A2 Beta-lactamyl vasopressin v1a antagonists |
| 07/07/2004 | EP1434624A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 07/07/2004 | EP1434599A1 Human 3 relaxin |
| 07/07/2004 | EP1434594A1 Cyclosporin analogs for the treatment of autoimmune diseases |
| 07/07/2004 | EP1434577A1 Pyrrolidinone derivatives |
| 07/07/2004 | EP1242404B1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 07/07/2004 | EP1235827B1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 07/07/2004 | EP1230222B1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/07/2004 | EP1073435B1 Substituted tricyclic pyrazole derivatives with protein kinase activity |
| 07/07/2004 | EP0946552B1 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 07/07/2004 | EP0918519B1 Therapeutic treatment for vegf related occular diseases |
| 07/07/2004 | CN1511157A Novel pyrrole derivatives as pharmaceutical agents |
| 07/07/2004 | CN1511155A Amido ether substituted imidazoquinolines |
| 07/07/2004 | CN1511154A Quinuclidines-substituted-multi-cycli-heteroaryls for treatment of disease |
| 07/07/2004 | CN1511151A 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives |
| 07/07/2004 | CN1511137A Hydro phobic polyamine analogs and methods for their use |
| 07/07/2004 | CN1511038A Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 07/07/2004 | CN1509746A Compound mingmu liquid preparing method |
| 07/07/2004 | CN1509715A Rifaximin drop |
| 07/07/2004 | CN1156492C Somatostatin peptides |
| 07/07/2004 | CN1156480C Water soluble SDZ-RAD esters, its preparation method, use and composition thereof |
| 07/07/2004 | CN1156454C Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/06/2004 | US6759534 Reacting benzofuran derivative with organolithium compound in presence of sulfur source; reacting with dichloropyridazine derivative, reacting with alkaline alkoxide in alkanol; reacting with mineral acid, oxidation |
| 07/06/2004 | US6759431 Compositions and methods for treating or preventing diseases of body passageways |
| 07/06/2004 | US6759424 Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them |
| 07/06/2004 | US6759422 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 07/06/2004 | US6759418 6-(((2s)-2-(alkoxycabonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3.4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or acid derivatives, useful for treating migraine, and dural protein extravasation |
| 07/06/2004 | US6759412 For producing drugs used for therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis |
| 07/06/2004 | CA2303594C Compounds for treating and preventing diabetic complications |
| 07/01/2004 | WO2004055154A2 Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness |
| 07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
| 07/01/2004 | WO2004054593A1 Ophthalmic compositions containing bile products from animal |
| 07/01/2004 | WO2004046199A3 Novel method of obtaining chondroitin sulphuric acid and uses thereof |
| 07/01/2004 | WO2004041859A3 Peptide fragments of the harp factor inhibiting angiogenesis |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2003103608A3 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 07/01/2004 | WO2003092584A3 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| 07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/01/2004 | WO2002100341A3 Compounds for the treatment of metabolic disorders |
| 07/01/2004 | US20040127707 Novel phthalazinones |
| 07/01/2004 | US20040127699 Cosmetics, drugs |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127532 Method for synthesizing leflunomide |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127508 Substituted pyrazolopyrimidines and thiazolopyrimidines |
| 07/01/2004 | US20040127472 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040126825 Using a compounds ability to decrease integrin activation as a diagnostic tool for the identification of antagonistic modulators of neovascularizaton; antitumor/antiproliferative agents |
| 07/01/2004 | US20040126801 Novel polynucleotides and encoded polypeptides |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126408 Bioerodible film for ophthalmic drug delivery |
| 07/01/2004 | US20040126382 Two-step immunization procedure against chlamydia infection |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432707A1 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432443A2 Angiotensin peptide-carrier conjugates and uses thereof |
| 06/30/2004 | EP1432420A2 Benzimidazolidinone derivatives as muscarinic agents |
| 06/30/2004 | EP1432419A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1214313B1 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/30/2004 | EP1149072B1 Sulfonamide hydroxamates |
| 06/30/2004 | EP1082299B1 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments |
| 06/30/2004 | EP0996465B1 Compositions and articles for reducing the effects of inflammation |
| 06/30/2004 | EP0876817B1 Remedy for keratoconjunctival diseases |
| 06/30/2004 | CN1509462A Use of NF-kappa-B inhibitors in treatment of dry disorders |
| 06/30/2004 | CN1509288A The citrate salt of 5,8,14-triazatetracyclo (10.3.1.0.2,11.0.4,9)-hexadeca-2.(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509276A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509274A Metallo proteinase inhibitors |
| 06/30/2004 | CN1509273A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509272A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509183A Use of proteasome inhibitors to treat dry eye disorders |
| 06/30/2004 | CN1509177A Method for treating dry eye disorders |
| 06/30/2004 | CN1509174A Tartrate salt of 5,8,14-triazatetracyclo [10,3,1,02,11.04,9]-hexzdeca-2(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509172A Pirenzepine ophthalmic gel |
| 06/30/2004 | CN1509171A Use of pyrazoline derivatives in preparation of medicament for prevention and/or treatment of proliferative cell diseases |
| 06/30/2004 | CN1507918A Transdermal promotor glycerin triacetate |
| 06/30/2004 | CN1155602C Thineopyranecarboxyamide derivatives |
| 06/30/2004 | CN1155600C 2,3-diaryl-pyrazolo[1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2(cox-2) inhibitors |
| 06/30/2004 | CN1155589C Compounds and methods for modulation of estroglen receptors |
| 06/30/2004 | CN1155383C Use of certain isoquinolinesulfonyl compounds for treatment of glaucoma and ocular ischemia |
| 06/29/2004 | US6756409 For therapy and prophylaxis of pain and/or neurodegenerative disorders |
| 06/29/2004 | US6756395 Cyclization of n-(4-cyanomethylphenyl)methanesulfonamides with ethylenediamine to form n-(4-imidazol-2-ylmethyl)-phenyl) -methanesulfonamides; incontinence, sexual dysfunction, nasal congestion, and cns disorders; alpha 1 adrenergic agonists |
| 06/29/2004 | US6756381 A purified antitumor agent is crystallized from acetone or dichloromethane |
| 06/29/2004 | US6756376 Preventing fatty acid release |
| 06/29/2004 | US6756371 Morpholino or thiomorpholino derivatives; respiratory system disorders |
| 06/29/2004 | US6756049 Sustained release drug delivery devices |
| 06/29/2004 | CA2105215C Novel oxazolidines |
| 06/24/2004 | WO2004052863A1 Anti-inflammatory agent |
| 06/24/2004 | WO2004028570A3 A method for treating severe tinnitus |
| 06/24/2004 | WO2004022716A3 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2003105724A3 Novel maxi-k channel blockers, methods of use and process for making the same |
| 06/24/2004 | WO2003103583A3 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |